UMIN ID: C000000190
Registered date:12/09/2005
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | Chronic hepatitis B |
Date of first enrollment | 2003/11/01 |
Target sample size | 10 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | Adefovir dipivoxil 10mg/day p.o. for at least 48 weeks |
Outcome(s)
Primary Outcome | HBV-DNA |
---|---|
Secondary Outcome | Serum ALT side effects |
Key inclusion & exclusion criteria
Age minimum | 16years-old |
---|---|
Age maximum | Not applicable |
Gender | Male and Female |
Include criteria | |
Exclude criteria | Allergy to lamivudine complication of chronic hepatitis C coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction |
Related Information
Primary Sponsor | Gunma Liver Study Group |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Gunma Liver Study Group |
Secondary ID(s) |
Contact
public contact | |
Name | Ken Sato |
Address | 3-39-22 Showa, Maebashi, Gunma 371-8511 Japan |
Telephone | 027-220-8127 |
satoken@showa.gunma-u.ac.jp | |
Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |
scientific contact | |
Name | Ken Sato |
Address | 3-39-22 Showa, Maebashi, Gunma 371-8511 Japan |
Telephone | 027-220-8127 |
satoken@gunma-u.ac.jp | |
Affiliation | Gunma University Graduate School of Medicine Department of Medicine and Molecular Science |